NeuBase Therapeutics Inc at Jefferies Healthcare Conference Transcript
Good morning. My name is Dietrich Stephan. I'm the CEO of NeuBase Therapeutics.
Terry Horgan died eight days after being dosed with a CRISPR/Cas9 gene editor delivered with an adeno-associated virus. The cause of death was an acute innate inflammatory response. In January 2023, Acowin report estimated that 36% of all gene editing programs utilize viral mediated delivery. These viruses -- these immunogenic viruses deliver a gene that expresses a bacterial protein in a human being that performs the editing.
This bacterial protein, even if delivered without a virus, can also cause an immune response. These immune responses can be dangerous and limit the ability to re-dose the editors should durability or pharmacology waned.
NeuBase has developed a nuclease-free gene-editing technology that is not delivered using viral vectors to completely synthetic platform, and it is delivered via nanoparticles. We view the evolution of the gene-editing space as you can see on this slide. The first generation of editors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
